Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex

Evidence from the I.Co.N.A. Study

Rita Murri, Alessandro Cozzi Lepri, Andrew N. Phillips, Enrico Girardi, Guglielmo Nasti, Sergio Ferrara, Maria Stella Mura, Cristina Mussini, Enzo Petrelli, Massimo Arlotti, Carlo De Stefano, Paola Vigano, Roberto Novati, Antonietta Cargnel, Antonella D'Arminio Monforte

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Objectives of the study were to assess the differences between sexes in the likelihood of starting antiretroviral therapy (ART), in rates of sustained discontinuation from highly active antiretroviral therapy (HAART), and in clinical progression. In a multicenter cohort study (I.Co.N.A. Study), 2323 men and 1335 women previously naive to antiretrovirals were enrolled. As of September 2002, 807 women and 1480 men started ART. The median time to starting ART was 28 weeks for women and 17 weeks for men (P = 0.0003 by log-rank test). This difference was no longer significant after adjusting for either HIV RNA (P = 0.21) or CD4 count (P = 0.28) at enrollment. Women tend to start HAART less frequently than mono/dual ART after adjusting for potential confounders (odds ratio = 0.78, 95% confidence interval [CI]: 0.60-1.01; P = 0.06). Women who started HAART were 1.4 times more likely than men (95% CI: 1.00-1.99; P = 0.05) to interrupt at least 1 drug because of toxicity. Twenty-one percent of women and 19% of men interrupted HAART altogether for more than 3 months (P = 0.3). Clinical progression was observed in 53 women (22.6%) and 137 men (23.4%; P = 0.56). Risk of developing a clinical event was found to be no different between women and men (relative hazard = 0.84, 95% CI: 0.56-1.26; P = 0.40).

Original languageEnglish
Pages (from-to)184-190
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume34
Issue number2
DOIs
Publication statusPublished - Oct 1 2003

Fingerprint

Incidence
Highly Active Antiretroviral Therapy
Confidence Intervals
Therapeutics
CD4 Lymphocyte Count
Drug-Related Side Effects and Adverse Reactions
Sex Characteristics
Multicenter Studies
Cohort Studies
Odds Ratio
HIV
RNA

Keywords

  • Access to care
  • Discontinuation
  • Highly active antiretroviral therapy
  • Survival
  • Toxicity
  • Women

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex : Evidence from the I.Co.N.A. Study. / Murri, Rita; Cozzi Lepri, Alessandro; Phillips, Andrew N.; Girardi, Enrico; Nasti, Guglielmo; Ferrara, Sergio; Mura, Maria Stella; Mussini, Cristina; Petrelli, Enzo; Arlotti, Massimo; De Stefano, Carlo; Vigano, Paola; Novati, Roberto; Cargnel, Antonietta; D'Arminio Monforte, Antonella.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 34, No. 2, 01.10.2003, p. 184-190.

Research output: Contribution to journalArticle

Murri, R, Cozzi Lepri, A, Phillips, AN, Girardi, E, Nasti, G, Ferrara, S, Mura, MS, Mussini, C, Petrelli, E, Arlotti, M, De Stefano, C, Vigano, P, Novati, R, Cargnel, A & D'Arminio Monforte, A 2003, 'Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study', Journal of Acquired Immune Deficiency Syndromes, vol. 34, no. 2, pp. 184-190. https://doi.org/10.1097/00126334-200310010-00008
Murri, Rita ; Cozzi Lepri, Alessandro ; Phillips, Andrew N. ; Girardi, Enrico ; Nasti, Guglielmo ; Ferrara, Sergio ; Mura, Maria Stella ; Mussini, Cristina ; Petrelli, Enzo ; Arlotti, Massimo ; De Stefano, Carlo ; Vigano, Paola ; Novati, Roberto ; Cargnel, Antonietta ; D'Arminio Monforte, Antonella. / Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex : Evidence from the I.Co.N.A. Study. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 34, No. 2. pp. 184-190.
@article{5fb94c0ff19d43e09fca72c64d9243a4,
title = "Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I.Co.N.A. Study",
abstract = "Objectives of the study were to assess the differences between sexes in the likelihood of starting antiretroviral therapy (ART), in rates of sustained discontinuation from highly active antiretroviral therapy (HAART), and in clinical progression. In a multicenter cohort study (I.Co.N.A. Study), 2323 men and 1335 women previously naive to antiretrovirals were enrolled. As of September 2002, 807 women and 1480 men started ART. The median time to starting ART was 28 weeks for women and 17 weeks for men (P = 0.0003 by log-rank test). This difference was no longer significant after adjusting for either HIV RNA (P = 0.21) or CD4 count (P = 0.28) at enrollment. Women tend to start HAART less frequently than mono/dual ART after adjusting for potential confounders (odds ratio = 0.78, 95{\%} confidence interval [CI]: 0.60-1.01; P = 0.06). Women who started HAART were 1.4 times more likely than men (95{\%} CI: 1.00-1.99; P = 0.05) to interrupt at least 1 drug because of toxicity. Twenty-one percent of women and 19{\%} of men interrupted HAART altogether for more than 3 months (P = 0.3). Clinical progression was observed in 53 women (22.6{\%}) and 137 men (23.4{\%}; P = 0.56). Risk of developing a clinical event was found to be no different between women and men (relative hazard = 0.84, 95{\%} CI: 0.56-1.26; P = 0.40).",
keywords = "Access to care, Discontinuation, Highly active antiretroviral therapy, Survival, Toxicity, Women",
author = "Rita Murri and {Cozzi Lepri}, Alessandro and Phillips, {Andrew N.} and Enrico Girardi and Guglielmo Nasti and Sergio Ferrara and Mura, {Maria Stella} and Cristina Mussini and Enzo Petrelli and Massimo Arlotti and {De Stefano}, Carlo and Paola Vigano and Roberto Novati and Antonietta Cargnel and {D'Arminio Monforte}, Antonella",
year = "2003",
month = "10",
day = "1",
doi = "10.1097/00126334-200310010-00008",
language = "English",
volume = "34",
pages = "184--190",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex

T2 - Evidence from the I.Co.N.A. Study

AU - Murri, Rita

AU - Cozzi Lepri, Alessandro

AU - Phillips, Andrew N.

AU - Girardi, Enrico

AU - Nasti, Guglielmo

AU - Ferrara, Sergio

AU - Mura, Maria Stella

AU - Mussini, Cristina

AU - Petrelli, Enzo

AU - Arlotti, Massimo

AU - De Stefano, Carlo

AU - Vigano, Paola

AU - Novati, Roberto

AU - Cargnel, Antonietta

AU - D'Arminio Monforte, Antonella

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Objectives of the study were to assess the differences between sexes in the likelihood of starting antiretroviral therapy (ART), in rates of sustained discontinuation from highly active antiretroviral therapy (HAART), and in clinical progression. In a multicenter cohort study (I.Co.N.A. Study), 2323 men and 1335 women previously naive to antiretrovirals were enrolled. As of September 2002, 807 women and 1480 men started ART. The median time to starting ART was 28 weeks for women and 17 weeks for men (P = 0.0003 by log-rank test). This difference was no longer significant after adjusting for either HIV RNA (P = 0.21) or CD4 count (P = 0.28) at enrollment. Women tend to start HAART less frequently than mono/dual ART after adjusting for potential confounders (odds ratio = 0.78, 95% confidence interval [CI]: 0.60-1.01; P = 0.06). Women who started HAART were 1.4 times more likely than men (95% CI: 1.00-1.99; P = 0.05) to interrupt at least 1 drug because of toxicity. Twenty-one percent of women and 19% of men interrupted HAART altogether for more than 3 months (P = 0.3). Clinical progression was observed in 53 women (22.6%) and 137 men (23.4%; P = 0.56). Risk of developing a clinical event was found to be no different between women and men (relative hazard = 0.84, 95% CI: 0.56-1.26; P = 0.40).

AB - Objectives of the study were to assess the differences between sexes in the likelihood of starting antiretroviral therapy (ART), in rates of sustained discontinuation from highly active antiretroviral therapy (HAART), and in clinical progression. In a multicenter cohort study (I.Co.N.A. Study), 2323 men and 1335 women previously naive to antiretrovirals were enrolled. As of September 2002, 807 women and 1480 men started ART. The median time to starting ART was 28 weeks for women and 17 weeks for men (P = 0.0003 by log-rank test). This difference was no longer significant after adjusting for either HIV RNA (P = 0.21) or CD4 count (P = 0.28) at enrollment. Women tend to start HAART less frequently than mono/dual ART after adjusting for potential confounders (odds ratio = 0.78, 95% confidence interval [CI]: 0.60-1.01; P = 0.06). Women who started HAART were 1.4 times more likely than men (95% CI: 1.00-1.99; P = 0.05) to interrupt at least 1 drug because of toxicity. Twenty-one percent of women and 19% of men interrupted HAART altogether for more than 3 months (P = 0.3). Clinical progression was observed in 53 women (22.6%) and 137 men (23.4%; P = 0.56). Risk of developing a clinical event was found to be no different between women and men (relative hazard = 0.84, 95% CI: 0.56-1.26; P = 0.40).

KW - Access to care

KW - Discontinuation

KW - Highly active antiretroviral therapy

KW - Survival

KW - Toxicity

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=0141923764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141923764&partnerID=8YFLogxK

U2 - 10.1097/00126334-200310010-00008

DO - 10.1097/00126334-200310010-00008

M3 - Article

VL - 34

SP - 184

EP - 190

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -